Literature DB >> 15170730

Gene therapy clinical trials worldwide 1989-2004-an overview.

Michael L Edelstein1, Mohammad R Abedi, Jo Wixon, Richard M Edelstein.   

Abstract

In 1989, Rosenberg et al. performed the first human gene therapy trial when they used a retrovirus to introduce the gene coding for resistance to neomycin into human tumor-infiltrating lymphocytes before infusing them into five patients with advanced melanoma. This study demonstrated the feasibility of using retroviral gene transduction in humans and set the stage for further studies. Since then, over 900 clinical trials have been completed, are ongoing or have been approved worldwide. These trials have been designed to establish feasibility and safety, to demonstrate the reality of expression of therapeutic protein(s) in vivo by the genes transferred and, in some cases, to show therapeutic benefit. There is no single source of information that presents an overview of all the clinical trials undertaken worldwide. In 1997 we set up a database to bring all the information on clinical trials together as comprehensively and as globally as possible. The data were compiled and are regularly updated from official agency sources, the published literature, presentations at conferences and from information kindly provided by investigators or trial sponsors themselves. As of January 31, 2004, we have identified 918 trials in 24 countries. The USA accounts for two-thirds of these trials. Cancer is by far the most common disease indication, followed by inherited monogenic diseases, and cardiovascular diseases. Viral vectors have been the most frequently used vehicles for transferring genes into human cells, with retroviruses and adenoviruses representing the vast majority. Plasmid (naked) DNA and other non-viral vectors have been used in one-quarter of the trials. Over 100 distinct genes have been transferred. This article aims to provide a descriptive overview of the clinical trials that, to the best of our knowledge, have been or are being performed worldwide. Details of the data presented, including an interactive, searchable database that currently holds information on 918 trials, can be found on The Journal of Gene Medicine clinical trials website 1. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15170730     DOI: 10.1002/jgm.619

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  78 in total

1.  Is ex vivo adenovirus mediated gene transfer a therapeutic option for the treatment of corneal diseases?

Authors:  T Ritter; N Gong; U Pleyer
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

2.  High-throughput, library-based selection of a murine leukemia virus variant to infect nondividing cells.

Authors:  Julie H Yu; David V Schaffer
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 3.  Cardiac fibrosis: potential therapeutic targets.

Authors:  Shuin Park; Ngoc B Nguyen; Arash Pezhouman; Reza Ardehali
Journal:  Transl Res       Date:  2019-03-09       Impact factor: 7.012

Review 4.  Lipid-based nanoparticles for nucleic acid delivery.

Authors:  Weijun Li; Francis C Szoka
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

5.  Computational and analytical modeling of cationic lipid-DNA complexes.

Authors:  Oded Farago; Niels Grønbech-Jensen
Journal:  Biophys J       Date:  2007-01-26       Impact factor: 4.033

Review 6.  Gene therapy in head and neck cancer: a review.

Authors:  E Chisholm; U Bapat; C Chisholm; G Alusi; G Vassaux
Journal:  Postgrad Med J       Date:  2007-12       Impact factor: 2.401

7.  Gene therapy, early promises, subsequent problems, and recent breakthroughs.

Authors:  Saeideh Razi Soofiyani; Behzad Baradaran; Farzaneh Lotfipour; Tohid Kazemi; Leila Mohammadnejad
Journal:  Adv Pharm Bull       Date:  2013-08-20

8.  Hypoxia/hepatoma dual specific suicide gene expression plasmid delivery using bio-reducible polymer for hepatocellular carcinoma therapy.

Authors:  Hyun Ah Kim; Kihoon Nam; Minhyung Lee; Sung Wan Kim
Journal:  J Control Release       Date:  2013-07-03       Impact factor: 9.776

Review 9.  High-level secretion of growth hormone by retrovirally transduced primary human keratinocytes: prospects for an animal model of cutaneous gene therapy.

Authors:  Cibele Nunes Peroni; Cláudia Regina Cecchi; Renata Damiani; Carlos R J Soares; Maria Teresa C P Ribela; Rosângela do Rocio Arkaten; Paolo Bartolini
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.695

10.  Self-assembly approaches to nanomaterial encapsulation in viral protein cages.

Authors:  Stella E Aniagyei; Christopher Dufort; C Cheng Kao; Bogdan Dragnea
Journal:  J Mater Chem       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.